VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2020

Nov 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2020-11-03

Reporting Person: Arbuckle Stuart A (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-03	Common Stock	M	1553	$86.52	Acquired	36732	Direct
2020-11-03	Common Stock	S	487	$210.56	Disposed	36245	Direct
2020-11-03	Common Stock	S	487	$211.54	Disposed	35758	Direct
2020-11-03	Common Stock	S	245	$212.38	Disposed	35513	Direct
2020-11-03	Common Stock	S	334	$214.13	Disposed	35179	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-03	Stock Option (Right to Buy)	$86.52	M	1553	Disposed	2027-02-02	Common Stock (1553)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $210.56 (range $210.00 to $210.97).

F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $211.54 (range $211.00 to $211.93).

F5: Open market sales reported on this line occurred at a weighted average price of $212.38 (range $212.18 to $212.63).

F6: Open market sales reported on this line occurred at a weighted average price of $214.13 (range $213.89 to $214.60).

F7: The option vests in 16 quarterly installments from 02/03/2017.